Biocon Q1 FY 2026-27 Results: Net Profit Surges Four-Fold To ₹141 Crore As Biosimilars Lead Growth

Demand for Biocon's biosimilars and generics gave the company a stronger start to FY27, helping earnings recover sharply from the subdued base seen a year ago. The improvement came even as its research services arm remained under pressure during the quarter.

In the Biocon Q1 FY 2026-27 results, the biopharmaceutical company posted a consolidated net profit of ₹141 crore, up from ₹31 crore in the corresponding period last year. Revenue from operations crossed the ₹4,300-crore mark as growth in its core businesses more than offset the decline in services revenue.

Key Highlights

• Revenue from Operations: ₹4,336 crore (up 10% YoY)

• Net Profit: ₹141 crore (up 355% YoY)

• Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA): ₹902 crore (up 7% YoY)

• EBITDA Margin: 21%

• Dividend: Not announced

• Biosimilars Revenue: ₹2,855 crore (up 16% YoY)

• Generics Revenue: ₹760 crore (up 21% YoY)

• Research Services Revenue: ₹736 crore (down 16% YoY)

How Did The Business Perform?

The Biocon Q1 FY 2026-27 results reflected a business driven largely by its biopharma portfolio. Biosimilars remained the biggest contributor during the quarter, generating ₹2,855 crore in revenue, while the generics business also posted healthy double-digit growth.

The company's research services division moved in the opposite direction, with revenue declining 16% from a year earlier. Even so, stronger performance from biosimilars and generics helped Biocon deliver overall revenue growth and a significant improvement in profitability.

The quarter also saw Biocon strengthen its global product portfolio. The company launched Bosaya and Aukelso, biosimilars of Denosumab, along with Yesafili, a biosimilar of Aflibercept, and generic Liraglutide in the United States.

Another milestone came from Europe, where the European Medicines Agency approved Biocon's insulin drug-product fill-finish facility in Malaysia. The approval is expected to support additional manufacturing capacity for the company's insulin business.

Management Commentary

CEO and Managing Director Shreehas Tambe said the company delivered a resilient start to the financial year, backed by disciplined execution and contributions from multiple businesses.

He noted that the recent product launches in the US, along with the European approval for the Malaysia insulin facility, have strengthened Biocon's manufacturing and commercial capabilities in key global markets.

Executive Chairperson Kiran Mazumdar-Shaw said the company has entered FY27 focused on converting its long-term investments into sustainable growth. She added that an improving policy environment for biosimilars and expanded manufacturing capacity in the US strengthen Biocon's long-term outlook, while investments in the research services business are expected to support its next phase of growth.

Market Reaction

Following the earnings announcement, Biocon share price traded higher during Wednesday's session. The stock closed at ₹425.20, up 0.76%, after touching an intraday high of ₹428.65 and a low of ₹422.30.

Also Read - Navin Fluorine Q1 FY 2026-27 Results